Literature DB >> 26864027

Comparison of commercial type 1 and type 2 PRRSV vaccines against heterologous dual challenge.

K Choi1, C Park1, J Jeong1, I Kang1, S-J Park1, C Chae1.   

Abstract

This study was to compare the effect of vaccination of pigs with either type 1 or type 2 porcine reproductive and respiratory syndrome virus (PRRSV) against heterologous dual challenge of both genotypes. Pigs were administered type 1 (UNISTRAIN PRRS) or type 2 (Fostera PRRS) PRRSV vaccine at 28 days of age and inoculated intranasally with both genotypes at 63 days of age. Vaccination of pigs with type 1 PRRSV was able to reduce the levels of type 1 but not type 2 PRRSV viraemia, whereas vaccination of pigs with type 2 PRRSV was able to reduce the levels of type 1 and type 2 PRRSV viraemia against a dual challenge. Vaccination of pigs with type 2 PRRSV significantly reduced lung lesions after dual challenge compared with vaccination of pigs with type 1 PRRSV. Vaccination of pigs with type 2 PRRSV induced higher numbers of type 1 and type 2 PRRSV-specific interferon-γ secreting cells compared with vaccination of pigs with type 1 PRRSV after dual challenge. The results of this study demonstrated that vaccination of pigs with type 2 PRRSV is efficacious in protecting growing pigs from respiratory disease after heterologous dual type 1 and type 2 PRRSV challenge compared with vaccination of pigs with type 1 PRRSV. British Veterinary Association.

Entities:  

Keywords:  Co-infection; Genotype; Porcine reproductive and respiratory syndrome; Vaccine

Mesh:

Substances:

Year:  2016        PMID: 26864027     DOI: 10.1136/vr.103529

Source DB:  PubMed          Journal:  Vet Rec        ISSN: 0042-4900            Impact factor:   2.695


  5 in total

1.  Cell-mediated immune response and protective efficacy of porcine reproductive and respiratory syndrome virus modified-live vaccines against co-challenge with PRRSV-1 and PRRSV-2.

Authors:  Adthakorn Madapong; Kepalee Saeng-Chuto; Alongkot Boonsoongnern; Angkana Tantituvanont; Dachrit Nilubol
Journal:  Sci Rep       Date:  2020-02-03       Impact factor: 4.379

Review 2.  Porcine Reproductive and Respiratory Syndrome Modified Live Virus Vaccine: A "Leaky" Vaccine with Debatable Efficacy and Safety.

Authors:  Lei Zhou; Xinna Ge; Hanchun Yang
Journal:  Vaccines (Basel)       Date:  2021-04-09

3.  Comparative evaluation of 4 commercial modified-live porcine reproductive and respiratory syndrome virus (PRRSV) vaccines against heterologous dual Korean PRRSV-1 and PRRSV-2 challenge.

Authors:  Taehwan Oh; Su-Jin Park; Hyejean Cho; Siyeon Yang; Hee Jin Ham; Chanhee Chae
Journal:  Vet Med Sci       Date:  2020-05-21

4.  Transcriptomic Analysis of Liver Indicates Novel Vaccine to Porcine Reproductive and Respiratory Virus Promotes Homeostasis in T-Cell and Inflammatory Immune Responses Compared to a Commercial Vaccine in Pigs.

Authors:  Damarius S Fleming; Laura C Miller; Jiuyi Li; Albert Van Geelen; Yongming Sang
Journal:  Front Vet Sci       Date:  2022-03-24

5.  Evaluation of a type 2 modified live porcine reproductive and respiratory syndrome vaccine against heterologous challenge of a lineage 3 highly virulent isolate in pigs.

Authors:  Fu-Hsiang Hou; Wei-Cheng Lee; Jiunn-Wang Liao; Maw-Sheng Chien; Chih-Jung Kuo; Han-Ping Chung; Min-Yuan Chia
Journal:  PeerJ       Date:  2020-03-30       Impact factor: 2.984

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.